Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lasmotinib - Pharos iBio

Next Previous
Drug Profile

Lasmotinib - Pharos iBio

Alternative Names: PHI-101

Latest Information Update: 28 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharos I&BT Co
  • Developer Pharos iBio; Seoul National University Hospital
  • Class Alkynes; Amides; Antineoplastics; Fluorobenzenes; Piperidines; Small molecules; Thiophenes; Urea compounds
  • Mechanism of Action Checkpoint kinase 2 inhibitors; Fms-like tyrosine kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Triple negative breast cancer
  • No development reported Acute myeloid leukaemia; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer

Most Recent Events

  • 28 Feb 2026 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in Australia (PO, Tablet)
  • 28 Feb 2026 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in South Korea (PO, Tablet)
  • 28 Feb 2026 No recent reports of development identified for phase-I development in Fallopian-tube-cancer(Recurrent, Second-line therapy or greater) in South Korea (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top